First human test for potential hepatitis b treatment
NCT ID NCT02535416
Summary
This early-stage study aimed to check the safety and see how the body processes a new experimental drug called ARC-520, which is designed to treat hepatitis B. It involved 40 healthy adult volunteers who received a single dose of the drug through an IV. The main goal was to find a safe way to give the drug and understand how it moves through and leaves the body.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site 1
Herston, Queensland, 4029, Australia
Conditions
Explore the condition pages connected to this study.